icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Treatment with Telaprevir/Peg-IFN/RBV After 14-day Telaprevir Exposure in Phase I Studies: Results from the Phase IIIB C219 Rollover Study
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
Christoph Sarrazin,1 Henk W Reesink,2 Stefan Zeuzem,1 Inge Dierynck,3 Don Luo,4 James Witek,4 Gaston Picchio,4 Sandra De Meyer3
1Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 2Academic Medical Center, Amsterdam, The Netherlands; 3Janssen Infectious Diseases, Beerse, Belgium; 4Janssen Research and Development LLC, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif